Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Brand And Generic Opioid Makers Agree: FDA Should Issue Guidance On Tamper Resistance

This article was originally published in The Pink Sheet Daily

Executive Summary

But Purdue and Teva disagree on the key question of whether a generic of a tamper-resistant analgesic must have the same dosage form as the reference-listed brand-name drug.

You may also be interested in...

Long-Acting Opioid REMS Tally: FDA Lists 12 Brand, 23 Generic

Nineteen companies will implement individual Risk Evaluation and Mitigation Strategies for long-acting/extended-release opioid products that are subject to the class-wide REMS unveiled by FDA July 9.

Pfizer Will Study Oxecta Abuse/Misuse Potential Post-Market

FDA okays the opioid, which contains abuse-resistant components, with labeling about a study that found the drug less likeable than immediate-release oxycodone.

Advisory Committee Sides With FDA: King/Acura's Acurox Fails To Prevent Abuse

The public forum did no favors for Acurox, as advisory committee members questioned whether adding niacin to oxycodone would really deter abuse.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts